openPR Logo
Press release

Investigation announced for Investors of PRA Health Sciences, Inc. (NASDAQ: PRAH) over Takeover

03-20-2021 09:07 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation on behalf of investors of PRA Health Sciences, Inc. (NASDAQ: PRAH) in connection with the proposed takeover.

An investigation on behalf of investors of PRA Health Sciences, Inc. (NASDAQ: PRAH) in connection with the proposed takeover.

An investigation was announced concerning whether the takeover of PRA Health Sciences, Inc.
is unfair to NASDAQ: PRAH stockholders.

Investors who purchased shares of PRA Health Sciences, Inc. (NASDAQ: PRAH) and currently hold any of those NASDAQ: PRAH shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain officers and directors of PRA Health Sciences, Inc. breached their fiduciary duties owed to NASDAQ: PRAH investors in connection with the proposed acquisition.

Raleigh, NC based PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. On Feb. 24, 2021, ICON plc, (NASDAQ: ICLR) announced it has entered into a definitive agreement to acquire PRA Health Sciences, Inc. (NASDAQ: PRAH) in a cash and stock transaction valued at approximately $12 billion, with the per share merger consideration consisting of $80 in cash and 0.4125 shares of ICON stock. Based on a closing price of $208.62 per NASDAQ: ICLR share on February 23, 201, investors in PRA Health Sciences, Inc. (NASDAQ: PRAH) will received a value of approximately of $166.06 per NASDAQ: PRAH shares.

However, given that at least one analyst has set the high target price of NASDAQ: PRAH shares at $196 per share, the investigation concerns whether the offer is unfair to NASDAQ: PRAH stockholders. More specifically, the investigation concerns whether the PRA Health Sciences Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.

Those who are current investors in PRA Health Sciences, Inc. (NASDAQ: PRAH) shares have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Investors of PRA Health Sciences, Inc. (NASDAQ: PRAH) over Takeover here

News-ID: 2259488 • Views: 510

More Releases from Shareholders Foundation

Lawsuit filed for Investors in shares of CytoDyn Inc. (OTC: CYDY)
An investor, who purchased shares of CytoDyn Inc. (OTC: CYDY), filed a lawsuit over alleged violations of Federal Securities Laws by CytoDyn Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of CytoDyn Inc. (OTC: CYDY) have certain options and for certain investors are short and strict deadlines running. Deadline: May 17, 2021. OTC: CYDY investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)
Investigation announced for Long-Term Investors in shares of SolarWinds Corporat …
An investigation on was announced concerning potential breaches of fiduciary duties by certain directors and officers of SolarWinds Corporation. Investors who are current long term investors in SolarWinds Corporation (NYSE: SWI) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NYSE: SWI stocks follows a lawsuit filed against SolarWinds Corporation
Update in Lawsuit for Investors in shares of Merit Medical Systems, Inc. (NYSE: …
An investor in Merit Medical Systems, Inc. (NYSE: MMSI) shares filed a lawsuit in December 2019, against Merit Medical Systems, Inc. over alleged violations of Federal Securities Laws. Investors who purchased shares of Merit Medical Systems, Inc. (NYSE: MMSI) prior to February 2019 and continue to hold any of those shares, have also certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. After the market
Deadline on May 3rd coming up in Lawsuit for Investors in Velodyne Lidar, Inc. ( …
A deadline is coming up on May 3, 2021 in the lawsuit filed for certain investors of Velodyne Lidar, Inc. (NASDAQ: VLDR) over alleged securities laws violations by Velodyne Lidar, Inc. Investors who purchased shares of Velodyne Lidar, Inc. (NASDAQ: VLDR) have certain options and there are strict and short deadlines running. Deadline: May 3, 2021. NASDAQ: VLDR stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -

All 5 Releases


More Releases for PRA

Pre Clinical CROs market 2027 Top Players : ovance, Inc., Charles River, Eurofin …
The global Pre Clinical CROs market is expected to reach US$ 8,412.9 Mn in 2027 from US$ 4,282.4 Mn in 2018. The market is estimated to grow with a CAGR of 8.1% from 2019-2027. The report highlights the trends prevalent in the global Pre Clinical CROs market and the factors driving the market along with those that act as deterrents to its growth. Request Sample Copy Of This Report @
Investigation announced for Long-Term Investors in shares of ProAssurance Corpor …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of ProAssurance Corporation was announced. Investors who are current long term investors in ProAssurance Corporation (NYSE: PRA) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NYSE: PRA stocks follows a lawsuit filed against ProAssurance
Contract Research Organization (CRO) Market 2020 Business Insights- Labcorp, IQV …
Global Contract Research Organization (CRO) Market 2020 offers detailed research and analysis of the COVID-19 impact provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global Contract Research Organization (CRO) market. Market participants can use the analysis on market dynamics to plan effective growth strategies and prepare for future challenges beforehand. Each trend of the global market is carefully analyzed
Preclinical CRO Market Emerging Growth Analysis, Business Opportunities and Majo …
Preclinical CRO treatment is likely to offer the knowledge, experience, and skill needed to take a pharmaceutical medical device or product from the drawing board to distribution. The preclinical contract research organizations (CRO) sector has witnessed a period of tremendous development in the past, profiting from quickly growing (R&D) spending. Several pharmaceutical companies have lost revenue owing to growing patent expirations thus encouraging several manufacturers to outsource factors of the
CRO Services Global Market 2018: Key Players – PPD, ICON, Algorithme, PRA, Syn …
CRO Services Industry Description Wiseguyreports.Com Adds “CRO Services -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2024” To Its Research Database Contract research organization (CRO) provide clinical trial and other research support services for the pharmaceutical, biotechnology, medical device industries and also serve government institutions, foundations and universities.  In 2018, the global CRO Services market size was xx million US$ and it is expected to reach xx million US$ by
Contract Research Organization Services (CROs) Market -Growth Strategies 2025 | …
Contract Research Organization Services (CROs): Snapshot Contract Research Organization or CRO is described as an organization which provide assistance and services generally to the pharmaceutical and biotechnology industries in the form of data research, drug tests, clinical trials, post development marketing, and related services for the development of both drugs and medical devices. CROs are available in a vast range from large, international full service organizations to small, niche specialty groups